108 related articles for article (PubMed ID: 8348032)
1. [The use of L-DOPA for treating myocardial infarct patients].
Bul'on VV; Khnychenko LK; Zavodskaia IS; Levina LI; Reznikova IS; Fedorov AIu
Eksp Klin Farmakol; 1993; 56(2):28-30. PubMed ID: 8348032
[TBL] [Abstract][Full Text] [Related]
2. [The clinical and hemodynamic effects of enalapril and its influence on the peri-infarct area in patients with an acute myocardial infarct].
Dobrotvorskaia TE; Shchukov AA; Gordina OV; Suprun EK; Shardanov NA; Kandoeva MM
Ter Arkh; 1994; 66(8):16-9. PubMed ID: 7985145
[No Abstract] [Full Text] [Related]
3. Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.
Davidson DF; Grosset K; Grosset D
Ann Clin Biochem; 2007 Jul; 44(Pt 4):364-8. PubMed ID: 17594783
[TBL] [Abstract][Full Text] [Related]
4. [The efficacy of Capoten in different clinical courses of acute myocardial infarct].
Mikashinovich ZI; Terent'ev VP; Shlyk SV; Suroedova RA; Shepelev AA
Anesteziol Reanimatol; 1996; (5):39-44. PubMed ID: 9027252
[No Abstract] [Full Text] [Related]
5. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
6. [Mechanisms of the effect of obsidan on the clinical picture of myocardial infarction at the early stage of the disease].
Andriushchenko OM
Klin Med (Mosk); 1989 Oct; 67(10):48-51. PubMed ID: 2615306
[TBL] [Abstract][Full Text] [Related]
7. [Use of neurotropic agents for treating and rehabilitating myocardial infarct patients].
Lebedeva MN; Bochkareva LE
Farmakol Toksikol; 1982; 45(6):34-7. PubMed ID: 6129999
[TBL] [Abstract][Full Text] [Related]
8. [Clinico-pharmacological study of neurotropic agents in neurogenic diseases of the cardiovascular system and stomach].
Zavodskaia IS; Moreva EV; Migas EA; Bul'on VV; Novikov VP
Farmakol Toksikol; 1983; 46(3):17-20. PubMed ID: 6861984
[TBL] [Abstract][Full Text] [Related]
9. [Coronarotropic drugs with general vasodilator action in the treatment of acute myocardial infarct].
Gherasim L; Cinteză M; Pârvu V; Dorobanţu M; Bogdan M; Dinulescu D; Popeia R; Vasilescu M
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1984; 36(5):385-95. PubMed ID: 6151225
[No Abstract] [Full Text] [Related]
10. [Effect of KIG polarizing mixture (potassium, insulin and glucose) on the adrenergic activity in early stage of myocardial infarct].
Hanzlik J; Sodolski W; Stelmasiak T; Zelazowska A
Kardiol Pol; 1980; 23(10):855-61. PubMed ID: 7007706
[No Abstract] [Full Text] [Related]
11. [Pharmacodynamic characteristics of a test using intravenous obzidan administration in patients with myocardial infarct].
Parkhomenko AN
Vrach Delo; 1988 Dec; (12):8-11. PubMed ID: 3245180
[No Abstract] [Full Text] [Related]
12. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
Fischer PA
J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
[TBL] [Abstract][Full Text] [Related]
13. [Use of terbutaline in patients with myocardial infarct and concomitant chronic obstructive diseases of the lungs].
Aksel'rud MM; Ustinov AG; Tatarskiĭ AR; Godiaev MIa; Zasimov AA
Sov Med; 1988; (3):61-4. PubMed ID: 3413553
[No Abstract] [Full Text] [Related]
14. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.
Hayashi M; Tsutamoto T; Wada A; Tsutsui T; Ishii C; Ohno K; Fujii M; Taniguchi A; Hamatani T; Nozato Y; Kataoka K; Morigami N; Ohnishi M; Kinoshita M; Horie M
Circulation; 2003 May; 107(20):2559-65. PubMed ID: 12732605
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
[TBL] [Abstract][Full Text] [Related]
16. [Hemodynamic variants of the acute period of uncomplicated myocardial infarct and the trends in their drug therapy].
Golovtsev IuIu
Vrach Delo; 1982 Jul; (7):32-6. PubMed ID: 7135899
[No Abstract] [Full Text] [Related]
17. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
18. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent.
Hornykiewicz O
Amino Acids; 2002; 23(1-3):65-70. PubMed ID: 12373520
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness of obzidan in patients with a history of myocardial infarct].
Il'iash MG
Vrach Delo; 1988 Mar; (3):47-9. PubMed ID: 3394297
[No Abstract] [Full Text] [Related]
20. [Treatment of patients with psychomotor epileptic attacks resistant to conventional anticonvulsant therapy].
Boldyrev AI; Sigidinenko LV
Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(6):60-1. PubMed ID: 2171274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
